Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences

Johan Fernø1, Silje Skrede, Audun O Vik-Mo

  • 1Dr. Einar Martens' Research Group for Biological Psychiatry and Bergen Mental Health, Research Center, Department of Clinical Medicine, University of Bergen, Norway. johan.ferno@haukeland.no

BMC Neuroscience
|October 21, 2006
PubMed
Abstract

Insights

Antipsychotic drugs show varied effects on lipogenesis-related gene expression in brain cells. Clozapine and chlorpromazine most potently activate sterol regulatory element-binding protein (SREBP) pathways, particularly in glial cells, suggesting a link to therapeutic efficacy.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Schizophrenia's etiology is unknown, but neurodevelopmental, myelin, and synaptic factors are implicated.
  • Cholesterol is vital for myelin and synapse formation.
  • Antipsychotics like clozapine and haloperidol activate lipogenic gene expression via sterol regulatory element-binding protein (SREBP) transcription factors.

Purpose of the Study:

  • To compare the effects of six antipsychotics (chlorpromazine, haloperidol, clozapine, olanzapine, risperidone, ziprasidone) on SREBP activation and target gene expression.
  • To investigate these effects in four human central nervous system (CNS)-relevant cell lines.

Main Methods:

  • Cultured human CNS-relevant cell lines (GaMg glioma, CCF-STTG1 astrocytoma, HCN2 cortical neurons, SH-SY5Y neuroblastoma) were treated with antipsychotics.
  • Sterol regulatory element-binding protein (SREBP) activation and expression of SREBP target genes (e.g., ACAT2, HMGCR, FASN) were measured.

Main Results:

  • Significant differences were observed in the ability of antipsychotics to activate SREBP target genes.
  • Clozapine and chlorpromazine were the most potent stimulators at therapeutic concentrations.
  • Glial-like cells (GaMg, CCF-STTG1) showed more pronounced SREBP activation than neuronal cells (HCN2, SH-SY5Y).

Conclusions:

  • Antipsychotics vary in their capacity to induce SREBP-controlled lipogenesis transcriptional activation in CNS cells.
  • This differential effect on lipogenesis may be relevant to the therapeutic efficacy of certain antipsychotic medications.

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...